Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients

June 2016 | Volume 15 | Issue 6 | Original Article | 670 | Copyright © 2016

David Lortscher MD,a Shehla Admani MD,b Nancy Satur MD,a and Lawrence F. Eichenfield MDb,c

aCurology Medical Group, San Diego, CA
bUniversity of California, San Diego, La Jolla, CA
cRady Children’s Hospital, San Diego, CA

This article is featured as a JDD Podcast, listen to the full discussion here.   Listen Here

Abstract

INTRODUCTION: Although hormonal contraceptives may help acne or worsen it, there is limited evidence on the effects of many commonly prescribed agents. The present study evaluates patient-reported effect on acne from 2147 patients who were utilizing a hormonal contraceptive at the time of their initial consultation for acne.
METHODS: At the time of initial consultation for acne, each of 2147 consecutive patients using hormonal contraception provided her assessment of how her contraceptive had affected her acne. The Kruskal-Wallis test and logistic regression analysis were used to compare patient-reported outcomes by contraceptive type.
RESULTS: Depot injections, subdermal implants, and hormonal intrauterine devices worsened acne on average, and were inferior to the vaginal ring and combined oral contraceptives (COCs; P ≤ .001 for all pairwise comparisons), which improved acne on average. Within COC categories, a hierarchy emerged based on the progestin component, where drospirenone (most helpful) > norgestimate and desogestrel > levonorgestrel and norethindrone (P ≤ .035 for all pairwise comparisons). The presence of triphasic progestin dosage in COCs had a positive effect (P = .005), while variation in estrogen dose did not have a significant effect (P = .880).
CONCLUSIONS: Different hormonal contraceptives have significantly varied effects on acne, including among types of COC.

J Drugs Dermatol. 2016;15(6):670-674.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

INTRODUCTION

Acne affects more than 70% of United States citizens at some point in their lives, and is associated with significant psychosocial and economic impact.1-3 Acne has a multifactorial pathogenesis that includes inflammation of the follicle and surrounding dermis, Propionibacterium acnes proliferation, abnormal follicular keratinization and increased sebum production associated with locally-produced or circulating androgenic hormones.4

Hormonal contraceptives contain a progestin component with or without an estrogen component. Estrogen components appear to inhibit acne by a variety of mechanisms including the feedback suppression of androgen production in the ovaries and increased synthesis of sex-hormone-binding globulin (SHBG), thereby reducing blood levels of free testosterone.5,6 Progestin components may have deleterious effects on acne, as many synthetic progestins cross-react with androgen receptors.7 However, some newer synthetic progestins, including cyproterone acetate and drospirenone, possess anti-androgenic activity.5,8

Progestin-only contraceptives include oral contraceptive pills, hormonal intrauterine devices (IUDs), depot injections, and subdermal implants. Contraceptives containing both an estrogen component and a progestin component include contraceptive patches, vaginal rings, and combined oral contraceptives (COCs).

The effect of any given hormonal contraceptive on acne may be mediated in part by the hormone type(s), the hormone dose(s), and the route of delivery. In order to assess the relative effects on acne of commonly prescribed hormonal contraceptives, this study analyzes self-reported data from 2147 consecutive female acne sufferers who were utilizing a hormonal contraceptive at the time of an initial teledermatology consultation for acne.

METHODS

Patients

The study was approved by the institutional review board at the University of California, San Diego School of Medicine. Deidentified information was collected from the medical records of 2147 consecutive female patients who were utilizing hormonal contraception at the time initial teledermatology consultation for acne between March 31, 2014 and May 18, 2015.

Data Collection

As part of an initial consultation, all female patients were given an intake questionnaire assessing if they were utilizing any form of hormonal contraception. Patients who answered “yes” were asked to record the type of contraceptive used and assess

↑ back to top


Related Articles